Guidant assures FDA of pledge to quality control
This article was originally published in Clinica
Executive Summary
Guidant underscored its commitment to enhancing its product quality systems in a recent letter to the US FDA, after concerns were raised by the agency following an inspection of the company's cardiac rhythm management (CRM) facility in September.